$-0.32 EPS Expected for NantKwest, Inc. (NK)

March 20, 2018 - By Adrian Erickson

 $ 0.32 EPS Expected for NantKwest, Inc. (NK)

Analysts expect NantKwest, Inc. (NASDAQ:NK) to report $-0.32 EPS on March, 21. The stock decreased 3.16% or $0.13 during the last trading session, reaching $3.98. About 271,094 shares traded or 6.55% up from the average. NantKwest, Inc. (NASDAQ:NK) has declined 40.03% since March 20, 2017 and is downtrending. It has underperformed by 56.73% the S&P500.

NantKwest, Inc. (NASDAQ:NK) Ratings Coverage

Among 7 analysts covering NantKwest (NASDAQ:NK), 4 have Buy rating, 1 Sell and 2 Hold. Therefore 57% are positive. NantKwest has $45 highest and $300 lowest target. $21.67’s average target is 444.47% above currents $3.98 stock price. NantKwest had 13 analyst reports since August 24, 2015 according to SRatingsIntel. FBR Capital initiated NantKwest, Inc. (NASDAQ:NK) on Wednesday, October 28 with “Outperform” rating. The firm has “Buy” rating given on Monday, August 24 by Jefferies. The stock of NantKwest, Inc. (NASDAQ:NK) earned “Market Perform” rating by Raymond James on Thursday, June 2. The rating was downgraded by Citigroup to “Sell” on Tuesday, May 16. The stock of NantKwest, Inc. (NASDAQ:NK) has “Buy” rating given on Monday, August 24 by MLV. The firm has “Overweight” rating given on Monday, August 24 by Piper Jaffray. The rating was maintained by Citigroup with “Neutral” on Monday, March 14. The stock has “Hold” rating by Jefferies on Tuesday, January 24. The company was initiated on Tuesday, December 22 by Canaccord Genuity. Citigroup initiated NantKwest, Inc. (NASDAQ:NK) on Monday, August 24 with “Buy” rating.

NantKwest, Inc., a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. The company has market cap of $314.55 million. The firm develops activated natural killer product candidates for the treatment of virally-induced cancers, such as polyoma virus induced merkel cell carcinoma, human papilloma virus induced cervical, and head and neck cancers; infectious diseases, including Ebola; and other serious viral, fungal, and bacterial infections. It currently has negative earnings. It is also develops high-affinity natural killer product candidates primarily for the treatment of solid tumors, breast cancer, head and neck/squamous, lymphoma, and various cancer; and target activated natural killer product candidates to treat hematological malignancies and solid tumors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.